Rising Number of Cancer Patients Expands Scope for Global NSCLC Market Health Articles | May 4 Wholesale Ben Gedeon Jersey , 2016
This report on the non-small cell lung cancer (NSCLC) Therapeutics market studies the current and future prospects of the global market. Non-small cell lung cancer is a type of lung cancer which accounted 85-90% of all lung cancers.
Non-small cell lung cancer (NSCLC) has been identified as the most common type of epithelial lung cancer. Adenocarcinomas, squamous cell carcinomas, and large cell carcinomas are the major types of NSCLC. Unlike small cell lung cancer (SCLC), NSCLC exhibits low receptivity to chemotherapy, owing to which, the need for NSCLC therapeutics has been persistently escalating in the global arena.
In this research report Wholesale Dalvin Cook Jersey , the global NSCLC market therapeutics has been evaluated on the basis of the drug class, the pipeline stage, and the regional spread of this market. Based on the drug class, the market has been classified into angiogenesis inhibitor, kinase inhibitor, epidermal growth factor receptor blocker Wholesale Anthony Barr Jersey , microtubule stabilizer, PD-1PD-L1 Inhibitor, and folate antimetabolites.
In 2014, angiogenesis inhibitor was the most demanded drug class in the global arena. The high efficiency of this drug class fueled its demand in the U.S., Japan, Europe Wholesale Everson Griffen Jersey , and other major regions.
Avastin and Cyramza are the two main angiogenesis inhibitors available in this market. Analysts expect this segment to expand at a CAGR of 1.80% during the forecast period and increase from a value of US$1.6 bn in 2014 to US$2 bn by the end of the forecast period.
Based on the pipeline stage, NSCLC therapeutics has been categorized into early-stage (phase 1 and phase 2) pipeline drugs and late-stage (phase 3) pipeline drugs. MEDI4736 (AstraZeneca), Avelumab (Pfizer Inc.), Abemaciclib (Eli Lilly and Co.), and MPDL3280A (Roche) are the major late-stage pipeline drugs.
Get a Free Sample of Report:聽
Regionally, the study segments the global market for NSCLC therapeutics into Asia Pacific Wholesale Kyle Rudolph Jersey , Europe, North America, and the Rest of the World. North America led the overall market in 2014 and was closely followed by Asia Pacific. However, Asia Pacific is anticipated to register the fastest growth rate over the forecast period.
The presence of state-of-art healthcare infrastructure and existence of a favorable reimbursement scenario are the key factors that drove the North America NSCLC therapeutics market. Besides, the growing awareness about NSCLC and the increasing implementation of government initiative to curb lung cancer are likely to boost the Asia Pacific market for NSCLC therapeutics in the coming years, notes the study.
AstraZeneca Plc Wholesale Linval Joseph Jersey , GlaxoSmithKline Plc, Genentech Inc., Eli Lilly & Co., Boehringer Ingelheim, Pfizer Inc., Celgene Corp. Wholesale Harrison Smith Jersey , Roche Holding AG, Sun Pharmaceutical Industries Ltd., and Bristol-Myers Squibb are some of the leading players in the global NSCLC therapeutics market, states the research report.
Early-Stage (Phase I and II) Late-Stage (Phase III) Avelumab Pfizer Inc.) MPDL3280A (Roche) MEDI4736 (AstraZeneca) Abemaciclib (Eli Lilly and Co.) Others
聽
Global Neurostimulation Devices Market Expected to Reach $xxx Million growing at a CAGR of xxx% by Planet Market Reports
by planetmarket_PMR · September 18, 2018
Neurostimulation Devices Market Size, Share and Forecast:
The Global market for Neurostimulation Devices is expected to cross US$5 Billion by the year end of 2021.
Drivers & Restraints
Market growth can be attributed to factors such as rising geriatric population Wholesale Kirk Cousins Jersey , increasing prevalence of neurological diseases, strong product pipeline offered by the players. In addition, rapid advances in the field of neurostimulation and development of minimally invasive techniques have greatly expanded the market. High cost of treatment and negative social perception is restraining the growth of neurostimulation devices Market.
Get a Free Sample Copy of this Report @
Segment Insights
Spinal cord stimulation segment dominated the neurostimulation devices market with more than XX% share in 2015. But its market share will dwindle in the forecasting period due to the highest growth rate of deep brain stimulation segment. It is expected that deep brain stimulation segment will grab nearly 20% market share by the year end of 2021.
Regional Insights
North America is seen as the dominant player in the neurostimulation devices market followed by Europe, Asia-Pacific, and rest of the world RoW in 2015. In the coming years, the neurostimulation devices market is expected to witness the highest growth rate in the Asian region Wholesale Adam Thielen Jersey , with emphasis on India, China, and Japan. These countries are expected to increase revenues for the manufacturers of devices involved in neurostimulation.
Only-Bests
Thema drucken
03.01.2020 09:28
Antworten
